Get the Stockscreener App
0.6475
3.77%
0.0235
Calcimedica Inc stock is traded at $0.6475, with a volume of 344.38K.
It is up +3.77% in the last 24 hours and up +5.99% over the past month.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
See More
Previous Close:
$0.624
Open:
$0.6115
24h Volume:
344.38K
Relative Volume:
0.32
Market Cap:
$9.44M
Revenue:
-
Net Income/Loss:
$-20.87M
P/E Ratio:
-0.4066
EPS:
-1.5924
Net Cash Flow:
$-21.21M
1W Performance:
+17.30%
1M Performance:
+5.99%
6M Performance:
-78.98%
1Y Performance:
-69.60%
1-Day Range:
$0.60
$0.67
1-Week Range:
$0.4606
$0.6932
52-Week Range:
$0.4606
$7.20
Calcimedica Inc Stock (CALC) Company Profile
Name
Calcimedica Inc
Sector
Industry
Phone
858-952-5500
Address
505 COAST BOULEVARD SOUTH, LA JOLLA
Compare CALC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CALC
Calcimedica Inc
|
0.655 | 8.99M | 0 | -20.87M | -21.21M | -1.5924 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.70 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.45 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
722.13 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.03 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.37 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Calcimedica Inc Stock (CALC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
Calcimedica Inc Stock (CALC) Latest News
Oppenheimer Adjusts CalciMedica Price Target to $10 From $20, Maintains Outperform Rating - marketscreener.com
CalciMedica price target lowered to $10 from $20 at Oppenheimer - TipRanks
CALC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Calcimedica Inc files for mixed shelf of up to $125 millionSEC filing - marketscreener.com
Calcimedica Inc Files For Mixed Shelf Of Up To $125 MillionSEC Filing - TradingView
CalciMedica (NASDAQ: CALC) files shelf to offer up to $125M in securities - Stock Titan
CalciMedica (NASDAQ: CALC) outlines Auxora pipeline, halted AKI trial and going concern risk - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
CALCForm 8-KCurrent report - ADVFN Ltd
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates - PR Newswire
Retail Trends: Whats next for CalciMedica Inc stock2025 Sector Review & Technical Entry and Exit Tips - baoquankhu1.vn
CALC Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
CALC SEC FilingsCALCIMEDICA INC 10-K, 10-Q, 8-K Forms - Stock Titan
Jobs Data: Is Vistagen Therapeutics Inc. stock a top pick in earnings seasonGold Moves & Reliable Intraday Trade Alerts - baoquankhu1.vn
Does CalciMedica Inc. meet Warren Buffett’s criteria2025 Stock Rankings & Weekly High Conviction Ideas - mfd.ru
Should I set a stop loss on CalciMedica Inc.July 2025 Momentum & Weekly Watchlist for Consistent Profits - mfd.ru
Aug Highlights: What’s the fair value of DUK.PRA stockQuarterly Trade Review & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Earnings Risk: Does CalciMedica Inc meet Warren Buffetts criteria2025 Price Momentum & Technical Pattern Recognition Alerts - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
How Is The Market Feeling About CalciMedica Inc? - Benzinga
What is CalciMedica Inc.’s book value per shareWeekly Trend Summary & AI Enhanced Trading Signals - mfd.ru
CalciMedica downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
This CalciMedica Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga
CalciMedica Shares Plunge After Discontinuing Phase II AKI Study - Citeline News & Insights
CalciMedica stock downgraded to Neutral by H.C. Wainwright after trial halt - Investing.com Canada
CalciMedica’s stock drops 75% on acute kidney injury trial termination - Clinical Trials Arena
CALC Stock Slumped 76% On Wednesday — Here’s Why - Asianet Newsable
CalciMedica discontinues AKI trial following safety concerns By Investing.com - Investing.com South Africa
CalciMedica discontinues Phase 2 KOURAGE trial following committee recommendation By Investing.com - Investing.com Nigeria
CalciMedica Discontinues Trial, Stock Faces Volatility - intellectia.ai
CalciMedica discontinues Phase 2 KOURAGE trial following committee recommendation - Investing.com
Calcimedica Discontinues Phase 2 Kourage Trial - TradingView
CalciMedica Ends KOURAGE Trial, Extends Cash Runway - TipRanks
Sector Update: Health Care - marketscreener.com
CalciMedica oversold on KOURAGE news, says Oppenheimer - TipRanks
CalciMedica ( CALC) Stock: Stops Phase 2 KOURAGE trial amid Enrollment Criteria Concerns - parameter.io
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Gold Jumps Over 4%; Seagate Shares Gain After Q2 Results - Benzinga
Calcimedica sags on halt of Auxora trial in acute kidney injury - bioworld.com
CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis - Benzinga
CalciMedica Shares Hit 52-Week Low After Ending Auxora Trial - marketscreener.com
Nasdaq Gains 150 Points; Starbucks Shares Rise After Strong Sales - Benzinga
CalciMedica stock craters as trial stopped over 'safety concern' - Fierce Biotech
CalciMedica tumbles as safety concerns halt trial of kidney injury drug - TradingView
CalciMedica stock plunges after discontinuing kidney injury trial By Investing.com - Investing.com Australia
CalciMedica stock plunges after discontinuing kidney injury trial - Investing.com
CalciMedica Halts Phase 2 KOURAGE Trial After Safety Review - TipRanks
CalciMedica discontinues AKI trial following safety concerns - Investing.com
CalciMedica announces discontinuation of Phase 2 KOURAGE clinical trial - TipRanks
CalciMedica Inc Discontinues Phase 2 KOURAGE Trial - TradingView
CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation - PR Newswire
Calcimedica Inc Stock (CALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):